AriBio Announces Completion of Enrollment in Phase 2 Alzheimer’s Study with AR1001
18.6.2020 03:00:00 EEST | Business Wire | Press release
AriBio, a clinical-stage biopharmaceutical company based in South Korea, announced today, June 17th 2020, the completion of enrollment in a Phase 2 study of AR1001, a first in class, orally dosed investigational drug for mild to moderate Alzheimer’s disease. A total of 210 patients are enrolled in the study, and the company is expecting to announce the topline results by early 2021.
“The completion of enrollment is a significant milestone for AriBio, and the company is extremely thankful for the combined efforts of our researchers, partners and the patient community. Advancing safe, effective and meaningful therapies for this devastating disease is our top priority at AriBio, and we look forward to presenting this data in the future,” said James Rock, Senior Vice President of Clinical Operations.
“Patients participating in the study are showing extremely low drop-out rates despite the COVID-19 pandemic and the safety profile of the drug has been encouraging,” said Matthew Choung, Chairman and CEO.
AriBio is the first company from South Korea to fully enroll a Phase 2 study for Alzheimer’s disease in the United States. The company aims to initiate another Phase 2 study for Mixed Dementia in 2021.
About AR1001
AR1001 is a first in class oral therapy with novel polypharmacological mechanisms for the treatment of Alzheimer’s disease. Pre-clinical studies have confirmed neuroprotective effects of AR1001 via inhibiting neuron apoptosis and restoring synaptic plasticity. AR1001 also has demonstrated positive effects against amyloid plaques and tau proteins.
About AR1001-ADP2-US01
AR1001-ADP2-US01 (NCT03625622) is A Double-Blind, Randomized and Placebo-Controlled Study to Evaluate Efficacy and Safety of 26-Week Treatment of AR1001 in Patients with Mild to Moderate Alzheimer's disease. The study aims to assess the safety and efficacy of AR1001 in slowing the progression of Alzheimer's disease through various cognitive and functional assessments. Last patient visit is expected to occur by the end of 2020. The details of the clinical trial are available at ClinicalTrials.gov.
About AriBio Co., Ltd.
AriBio Co., Ltd. is a biopharmaceutical company based in South Korea with a focus on neurodegenerative and infectious diseases. AR1003 is the lead candidate for sepsis and COVID-19, which is preparing to enter a Phase 1 study in the United States by early 2021.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200617005630/en/
Contact information
Fred Kim
734-516-8732
fredkim@aribiousa.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ruler of Ras Al Khaimah Inaugurates the First Ras Al Khaimah’s Business Consultancy in China, Strengthening Ties With Guangdong22.10.2026 00:46:00 EEST | Press release
HH Sheikh Saud bin Saqr Al Qasimi, UAE Supreme Council Member and Ruler of Ras Al Khaimah, inaugurated the Emirate’s first business consultancy in China, marking a new chapter of cooperation and partnership. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261021542126/en/ His Highness Sheikh Saud bin Saqr Al Qasimi, UAE Supreme Council Member and Ruler of Ras Al Khaimah, inaugurated the Emirate’s first business consultancy in China, located in Guangzhou, Guangdong Province, stating that the launch reflects a long-term commitment to strengthening ties with partners in China and to creating new avenues for investment, trade and collaboration. (Photo: AETOSWire) Located in the industrial hub of Guangzhou, the consultancy will serve as a leading platform dedicated to strengthening Ras Al Khaimah’s engagement with Chinese businesses, facilitating expanding cooperation across key sectors. The inauguration builds on a relationship t
Octane AI Launches Phoenix, an AI Quiz Builder That Builds, Checks and Improves Quizzes for Shopify Brands21.10.2026 20:15:00 EEST | Press release
Octane AI, the quiz and zero-party data platform for Shopify brands, launched Phoenix in October, its biggest release to date. Merchants describe the quiz they want or upload what they already have, and Phoenix builds it, checks it, personalizes the results and keeps improving it with experiments. One beta customer turned a single document into a complete product-launch quiz: “I attached it to Phoenix, and it built the whole thing, all the pages. It understood everything, not just the text but the logic behind it.” Across all live Octane AI quizzes, 15% of shoppers who finish a quiz place an order. Yet building one has meant hours of writing rules by hand, custom code for design and clicking through every path to find broken results. Phoenix handles those hard parts, from building a quiz to improving it after launch. “Since day one, we've kept track of every piece of feedback from our merchants: what frustrates them and what they wish Octane AI could do. Phoenix is the result, and it k
Cognite Earns Corporate Supplier of the Year Award from Marathon Petroleum Corporation21.10.2026 20:06:00 EEST | Press release
Cognite today announced it has been named Corporate Supplier of the Year winner in Marathon Petroleum Corporation’s 11th Annual Supplier Recognition Awards. The Supplier Recognition Awards is a program sponsored by Marathon Petroleum Corporation to honor suppliers that positively impacted the company’s business throughout the previous calendar year. “There’s a reason ‘Impact’ is one of Cognite’s most important core values,” said Girish Rishi, CEO of Cognite. “For us, the ultimate measure of our performance is delivering quantifiable value for our customers. From that perspective, the Corporate Supplier of the Year award from Marathon is particularly meaningful. Marathon Petroleum is an innovator, and to receive this recognition is a great honor to the Cognite community.” The Supplier of the Year Award from Marathon is the latest honor Cognite has received in 2026: In May, Cognite ranked 15th on CNBC’s Disruptor50 list, honoring venture-backed companies innovating across industries, exp
The Estée Lauder Companies Inc. to Webcast Capital Markets Experience: China Ecosystem Immersion Presentations on November 4, 202621.10.2026 19:48:00 EEST | Press release
The Estée Lauder Companies Inc. (NYSE: EL) today announced that it will webcast presentations from its Capital Markets Experience: China Ecosystem Immersion in Shanghai, China, on Wednesday, November 4, 2026. The event will feature presentations from Stéphane de La Faverie, President and Chief Executive Officer, and Akhil Shrivastava, Executive Vice President and Chief Financial Officer, as well as members of the Company’s Executive Leadership Team and local leaders. The presentations will highlight the Company’s strategy and capabilities in China, Beauty Reimagined in action, and how China serves as a blueprint for deploying the Company’s global capabilities to drive sustainable growth and stronger profitability. Due to limited capacity, in-person attendance is by invitation only. Interested parties can access the live webcast on Wednesday, November 4th, beginning at 1:00 p.m. China Standard Time (12:00 a.m. ET) at Investors – The Estée Lauder Companies Inc. A replay of the webcast wi
Future Health and Bridge for Billions to Launch Programme Strengthening Health Entrepreneurship in Emerging Markets21.10.2026 18:50:00 EEST | Press release
Future Health – A Global Initiative by Abu Dhabi and Bridge for Billions will launch a new entrepreneurship programme designed to strengthen promising health ventures in emerging markets and help locally-developed solutions reach more people. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261021719421/en/ The first phase of the programme will target around 50 entrepreneurs leading late-incubation to early-acceleration ventures in Africa and Asia. Emerging markets are home to significant health needs and entrepreneurial potential, yet many promising ventures can struggle to access the capital, specialist guidance, and health-system connections required to grow. WIPO’s Global Innovation Index 2024 reported that Latin America and Africa together accounted for around 3% of global venture-capital deals in the first half of 2024, while venture-capital values fell by 19% in Asia-Pacific and 80% in Africa. At the same time, entrepre
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom